两性霉素 B 和米卡芬净双载纳米乳作为一种对抗生物膜的潜在策略。

Amphotericin B and micafungin duo-loaded nanoemulsion as a potential strategy against biofilms.

机构信息

Department of Biological Sciences, São Paulo State University (UNESP), School of Pharmaceutical Sciences, São Paulo State, Brazil.

Department of Drug and Medicines, São Paulo State University (UNESP), School of Pharmaceutical Sciences, São Paulo State, Brazil.

出版信息

Biofouling. 2024 Oct;40(9):602-616. doi: 10.1080/08927014.2024.2396020. Epub 2024 Sep 8.

DOI:10.1080/08927014.2024.2396020

PMID:39245976

Abstract

is a multidrug-resistant yeast that has seen a worrying increase during the COVID-19 pandemic. Give7/n this, new therapeutic options, such as controlled-release nanomaterials, may be promising in combating the infection. Therefore, this study aimed to develop amphotericin B (AmB) and micafungin (MICA)-loaded nanoemulsions (NEMA) and evaluated against biofilms of . Nanoemulsions (NEs) were characterized and determined minimum inhibitory concentration MIC, checkerboard and anti-biofilm. NEMA presented a size of 53.7 and 81.4 nm for DLS and NTA, respectively, with good stability and spherical morphology. MICAmB incorporated efficiency was 88.4 and 99.3%, respectively. The release results show that AmB and MICA obtained a release of 100 and 63.4%, respectively. MICAmB and NEMA showed MIC90 values of 0.015 and 0.031 ug/mL, respectively and synergism. NEMA showed greater metabolic inhibition and morphological changes in mature biofilms. This drugs combination and co-encapsulation proved to be a promising therapy against biofilms.

摘要

是一种具有多重耐药性的酵母，在 COVID-19 大流行期间其数量令人担忧地增加。鉴于此，新的治疗选择，如控释纳米材料，可能在对抗感染方面具有广阔的前景。因此，本研究旨在开发两性霉素 B（AmB）和米卡芬净（MICA）负载的纳米乳剂（NEMA），并对其进行评估，以对抗的生物膜。对纳米乳剂（NEs）进行了表征，并测定了最低抑菌浓度（MIC）、棋盘法和抗生物膜活性。DLS 和 NTA 分别测定 NEMA 的粒径为 53.7 和 81.4nm，具有良好的稳定性和球形形态。AmB 的包封效率分别为 88.4%和 99.3%。释放结果表明，AmB 和 MICA 的释放量分别达到 100%和 63.4%。MICAmB 和 NEMA 的 MIC90 值分别为 0.015 和 0.031μg/mL，表现出协同作用。NEMA 对成熟生物膜表现出更大的代谢抑制和形态变化。这种药物联合和共包封被证明是一种有前途的治疗生物膜的方法。